Objective: To investigate the clinical efficacy of using ultrasound-guided Mammotome revolve device in treatment of early-stage breast cancer.
Methods: The clinical data of 51 patients who underwent complete lesion excision by ultrasound-guided Mammotome revolve device and then radical surgery because pathologically diagnosed as breast cancer after lesion excision between January 2015 and June 2018 were collected. The residual tumor in the margin of the resection cavity and the risk factors for residual tumor were analyzed.
Results: Of the 51 patients, residual tumor was detected in 15 cases (29.4%). After diagnosis of breast cancer, 37 patients underwent mastectomy, and 14 patients received breast-conserving radical surgery with resection of the needle passage, and no residual tumor was found in the needle passage by pathological examination in any of the 14 cases. The results of univariate analysis showed that the history of breast cancer, histological type of the tumor, histological grade, hormone receptors and status of the axillary lymph nodes had no significant influence on tumor residues(all P>0.05); tumor diameter (P=0.046), age(P=0.036) and high Ki-67expression(P=0.039) were associated with tumor residues. Results of multivariate analysis revealed that high Ki-67 expression was an independent risk factor for tumor residues (OR=4.83, P=0.038).
Conclusion: There is a relatively high rate of residual tumor after early-stage breast cancer excision by ultrasound-guided Mammotome revolve device, so indications should be rigorously followed to reduce the chance of residual tumor.However, its clinical value needs to be further evaluated.